ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 10| Issue: 11| November 2024|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2024: 8.402|| ISI Value

A COMPLETE STUDY OF DRUG TO CONTROL HEART ATTACK

Mr. Avinash D. Hatkar[1], Mr. Chaitanya Bhaskar Nagre[2]*, Mr. Sandip Phoke[3], Dr. Sunil Jaybhaye[4], Mr. Pooja Mule[5],

[1]*Faculty of Pharmacy, Department Dr. Babasaheb Ambedkar Technological University, Raigad, Lonere*
[2]*Student of Bachelor in Pharmacy, Dr. Babasaheb Ambedkar Technological University, Raigad, Lonere.*
[3]*Faculty of Pharmacy, Department, Dr. Babasaheb Ambedkar Technological University, Raigad, Lonere*
[4]*Faculty of Pharmacy Department, Dr. Babasaheb Ambedkar Technological University, Raigad, Lonere*
[5]*Faculty of Pharmacy Department, Dr. Babasaheb Ambedkar Technological University, Raigad, Lonere*
Institute of Pharmacy, (NKSPT) Pathrikar Campus, Badnapur, Jalna 431202

ABSTRACT

Autonomic functions, such as increased sympathetic and parasympathetic activity and the brain's suprachiasmatic nucleus, higher nervous centres, depression, hostility and aggression appear to be important determinants of heart rate variability (HRV), which is, itself, an important risk factor of myocardial infarction, arrhythmias, sudden death, heart failure and atherosclerosis. The circadian rhythm of these complications with an increased occurrence in the second quarter of the day may be due to autonomic dysfunction as well as to the presence of excitatory brain and heart tissues.

Recent studies indicate that there is an interaction between biorhythms, the biological clock and triggers, which may be important in the pathogenesis of altered heart rate variability (HRV) and blood pressure variability (BPV). Circadian rhythms are under the influence of, and physiological variables are mediated by the activation of the adrenals, sympathetic/parasympathetic, hypothalamic and pituitary activity. Emotional stress, physical exertion, sleep deprivation and large fatty meals are major triggers of myocardial ischemia, angina, infarction, sudden cardiac death (SCD) and stroke.

KEYWORD ; *Heart attack , What , Type , Risk , Drug , Control , History.*

HEART ATTACK

A heart attack occurs when an artery that sends blood and oxygen to the heart is blocked. Fatty, cholesterol-containing deposits build up over time, forming plaques in the heart's arteries. If a plaque ruptures, a blood clot can form. The clot can block arteries, causing a heart attack. During a heart attack, a lack of blood flow causes the tissue in the heart muscle to die. A heart attack is also called a myocardial infarction.

Prompt treatment is needed for a heart attack to prevent death. Call 911 or emergency medical help if you think you might be having a heart attack. {1}




Fig No.1

- **What is a Heart Attack?**

The coronary arteries carry blood to the heart, allowing it to function. A heart attack, also known as a myocardial infarction, occurs when a blockage develops in the coronary arteries and restricts the flow of blood to the heart.

Blockages occur when fat, cholesterol, and other substances build up, forming deposits called plaques in blood vessels. These plaques can become damaged over time and may release platelets.

Platelets can cause the blood to clot. They may collect around a plaque, eventually blocking blood flow.

By restricting blood flow, these blockages can damage the heart muscle. The severity of damage will depend on the size of the blockage. When blood is not reaching a significant segment of the heart, the damage will be more extensive.

A cardiac arrest is often mislabelled as a heart attack. However, a cardiac arrest occurs when the heart abruptly stops working.

- **Types**

A heart attack results from one of the following types of coronary artery disease:

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 10| Issue: 11| November 2024|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2024: 8.402|| ISI Value

- **STEMI**

A STEMI heart attack is severe and requires immediate attention.

These attacks occur when the coronary artery is fully blocked, preventing blood from reaching a large area of the heart. This causes progressive damage to the heart muscle, which can eventually stop it from functioning.




Fig No.2

- **NSTEMI**

NSTEMI heart attacks occur when the coronary artery is partially blocked and blood flow is severely restricted. While they are less dangerous than STEMI heart attacks, they can cause permanent damage.




Fig No.3

- **Coronary Artery Spasm**

These spasms are also called silent heart attacks or unstable angina. They occur when the arteries connected to the heart contract, preventing or restricting blood flow to the heart.

Symptoms do not cause permanent damage, and they are less severe than those of other types of coronary artery disease.

It is possible to mistake a coronary artery spasm for a minor condition, such as indigestion. However, having a coronary artery spasm can increase the risk of having a more severe heart attack.




Fig No.4

Risk Factors

Heart Attack Risk Factors Include

Age. Men age 45 and older and women age 55 and older are more likely to have a heart attack than are younger men and women.

Tobacco use. This includes smoking and long-term exposure to secondhand smoke. If you smoke, quit.

High blood pressure. Over time, high blood pressure can damage arteries that lead to the heart. High blood pressure that occurs with other conditions, such as obesity, high cholesterol or diabetes, increases the risk even more.

High Cholesterol or triglycerides. A high level of low-density lipoprotein (LDL) cholesterol (the "bad" cholesterol) is most likely to narrow arteries. A high level of certain blood fats called triglycerides also increases heart attack risk. Your heart attack risk may drop if levels of high-density lipoprotein (HDL) cholesterol — the "good" cholesterol — are in the standard range.

Obesity. Obesity is linked with high blood pressure, diabetes, high levels of triglycerides and bad cholesterol, and low levels of good cholesterol.

Diabetes. Blood sugar rises when the body doesn't make a hormone called insulin or can't use it correctly. High blood sugar increases the risk of a heart attack.

Metabolic syndrome. This is a combination of at least three of the following things: enlarged waist (central obesity), high blood pressure, low good cholesterol, high triglycerides and high blood sugar. Having metabolic syndrome makes you twice as likely to develop heart disease than if you don't have it.

Family history of heart attacks. If a brother, sister, parent or grandparent had an early heart attack (by age 55 for males and by age 65 for females), you might be at increased risk.

Not Enough Exercise. A lack of physical activity (sedentary lifestyle) is linked to a higher risk of heart attacks. Regular exercise improves heart health.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 10| Issue: 11| November 2024|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2024: 8.402|| ISI Value

Unhealthy Diet. A diet high in sugars, animal fats, processed foods, trans fats and salt increases the risk of heart attacks. Eat plenty of fruits, vegetables, fiber and healthy oils.
Stress. Emotional stress, such as extreme anger, may increase the risk of a heart attack.

Illegal Drug Use. Cocaine and amphetamines are stimulants. They can trigger a coronary artery spasm that can cause a heart attack.
A History of Preeclampsia. This condition causes high blood pressure during pregnancy. It increases the lifetime risk of heart disease.

An Autoimmune Condition. Having a condition such as rheumatoid arthritis or lupus can increase the risk of a heart attack. {1}

- **Complications**

Heart attack complications are often due to heart muscle damage. Potential complications of a heart attack include

Irregular or atypical heart rhythms (arrhythmias): Heart attack damage can affect how electrical signals move through the heart, causing heartbeat changes. Some may be serious and can be deadly.

Cardiogenic Shock: This rare condition occurs when the heart is suddenly and abruptly unable to pump blood.

Heart Failure. A lot of damage to the heart muscle tissue can make the heart unable to pump blood. Heart failure can be temporary or long-lasting (chronic).
Cardiac arrest. Without warning, the heart stops. A sudden change in the heart's signaling causes sudden cardiac arrest. A heart attack increases the risk of this life-threatening condition. It can lead to death (sudden cardiac death) without immediate treatment. [1]

- **Types of Medications**

Heart attack treatment involves a variety of drugs. The following list provides an overview of the common types. You can also learn about cardiac medications in more detail.
Your health care team will recommend the best combination of medications for your situation.

1. **Anticoagulant:** Sometimes called blood thinners, these medicines make it harder for clots to form and also keep existing blood clots from getting larger.
2. **Antiplatelet agent:** Keeps blood clots from forming by preventing blood platelets from sticking together.
3. **Angiotensin-converting enzyme (ACE) inhibitor:** Relaxes blood vessels and allows them to expand while decreasing resistance by lowering levels of angiotensin II. Allows blood to flow more easily and makes the heart's work easier or more efficient.
4. **Angiotensin II receptor blocker:** These medicines inhibit angiotensin II from having effects on the heart and blood vessels. This keeps blood pressure from rising.
5. **Angiotensin receptor neprilysin inhibitor:** Neprilysin is an enzyme that breaks down natural substances in the body that open narrowed arteries. By inhibiting neprilysin, those natural substances can have their normal effect. That improves artery opening and blood flow, reduces sodium (salt) retention and decreases strain on the heart.
6. **Beta blocker:** Makes the heart beat slower and with less force, which lowers blood pressure.
7. **Combined alpha and beta blocker:** Combined alpha and beta blockers may be used as an IV drip for people in hypertensive crisis. They may be prescribed for outpatient high blood pressure use if the person is at risk for heart failure.
8. **Calcium channel blocker:** Interrupts the movement of calcium into the cells of the heart and blood vessels. May decrease the heart's pumping strength and relax the blood vessels.
9. **Cholesterol-loweringmedications:** Various medications can lower blood cholesterol levels, but statins are the best first course of action. When statins don't work, or if a person has serious side effects from statin therapy, other drugs may be recommended
10. **Vasodilator:** Relaxes blood vessels and increases the supply of blood and oxygen to the heart while reducing its workload. Available as pills to be swallowed, chewable tablets and as a topical application (cream).

- **Dual Antiplatelet Therapy (DAPT)**

Some people who have heart attacks, that have stents placed in their coronary arteries, or undergo coronary artery bypass graft surgery (CABG) are treated with two types of antiplatelet agents at the same time to prevent blood clotting. This is called dual antiplatelet therapy (DAPT).

One antiplatelet agent is aspirin. Many people with coronary artery disease, including those who have had a heart attack, stent or CABG are treated with aspirin for the rest of their lives. A second type of antiplatelet agent, called a $P2Y_{12}$ inhibitor, is usually prescribed for months or years in addition to the aspirin therapy.

The type of medication and the duration of your treatment will vary based on your condition and other risk factors. The risks and benefits of DAPT should be discussed with your health care professional.

If you had a heart attack and a coronary artery stent placed, or you are being treated with medical therapy (no stent, clot buster or surgery), in addition to aspirin, you should speak with your health care professional about taking a $P2Y_{12}$ inhibitor for 6-12 months. In some cases, it may be advisable to be on DAPT longer.

You may be prescribed one of the following: clopidogrel, ticlopidine, prasugrel, ticagrelor or cangrelor. You will be prescribed the drug that is best for you, based on your risk of blood clots and bleeding. The choice of what type of medication and duration of treatment will be determined in discussions with your health care professional.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 10| Issue: 11| November 2024|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2024: 8.402|| ISI Value

DRUG USE TO CONTROL HEART ATTACK

1.Aspirin

- **Aspirin Therapy in Heart Disease**
  Your healthcare provider may recommend low-dose aspirin therapy to reduce your risk of heart attack and stroke if you have cardiovascular disease. Aspirin therapy may be beneficial, especially if you have a history of these conditions. Talk with your healthcare provider about whether aspirin therapy for heart disease is right for you.

- **What is aspirin therapy for heart disease?**
  If you are at risk for cardiovascular disease, your healthcare provider may recommend you take a daily low dose of aspirin. Aspirin therapy can help lower your risk of heart attack and stroke, especially if you've had these conditions previously.

- **How does aspirin therapy help prevent heart disease?**
  Taking aspirin daily, known as an aspirin regimen, reduces your risk of heart attack and stroke. Aspirin thins your blood and helps prevent blood clots that can cause these conditions

- **What is low-dose aspirin therapy?**
  People on low-dose aspirin therapy typically take 81 milligrams each day, sometimes known as baby aspirin. Healthcare providers may recommend a different aspirin dose for some people. Talk to your provider about whether aspirin therapy is right for you and how much you should take.

- **Who might benefit from aspirin therapy?**
  You may benefit from taking a low-dose aspirin every day if you have:
- Diabetes.
- High blood pressure (hypertension).
- A history of smoking.
- Hyperlipidemia (high cholesterol).
- Coronary artery disease.
- Peripheral artery disease.
- History of heart attack or stroke.

If you have a history of stroke or heart attack, talk to your healthcare provider. Aspirin therapy may help prevent a second heart attack or stroke.

- **How effective is aspirin therapy for heart disease?**

Aspirin therapy can have a significant impact on lowering your risk of having a heart attack or stroke. This is especially true in people with multiple risk factors, such as high cholesterol, high blood pressure, and diabetes. Always talk to your provider before taking aspirin for heart disease.

- **Who should not take low-dose aspirin for heart disease?**

Aspirin therapy may not be right for you if you are pregnant or you have:

1. Asthma.
2. Bleeding disorders, such as hemophilia or Von Willebrand disease.
3. Stomach ulcers.
4. Kidney disease.
5. Liver disease.[4]

2.Colchicine's

Colchicine's Role in Cardiovascular Disease Management
Colchicine has long seen use as an anti-inflammatory treatment for gout and familial Mediterranean fever. Beginning in the 20th century, randomized clinical trials established low-dose colchicine as an effective treatment for pericarditis and atherosclerotic cardiovascular disease, 2 conditions driven by the NLRP3 inflammasome and interleukin-1. The mechanisms through which colchicine exerts its beneficial anti-inflammatory and cardiovascular effects remain an area of vigorous investigation. When prescribing colchicine, clinicians must consider drug-drug interactions, impaired kidney and liver function, and adverse effect monitoring.

This Review follows the journey of colchicine from a herbal medicine used to treat joint swelling and pain through its contemporary use in cardiovascular disease. We discuss the effects of colchicine on immune cells, highlight landmark clinical trials, and consider the practical aspects of colchicine use.

- **BRIEF HISTORY OF COLCHICINE**

Hartung[8] published an authoritative review of the history of colchicine based on careful examination of several dozen historical documents. The earliest medical use of colchicine possibly dates to 1500 BCE based on writings that describe the use of a plant likely containing colchicine for the treatment of pain and swelling In the 550s CE, Alexander of Tralles, a physician in the Byzantine Empire, described the use of hermodactyl, a plant resembling the Autumn crocus, for the treatment of gout as well as the botanical's adverse gastrointestinal effects. Baron Anton Stork provided an early description of the use of colchicine for pericarditis in the 18th century. Around the same time, Nicolas Husson developed the first commercial colchicine preparation: Eau Medicinale.

ase reports and clinical trials established the efficacy of colchicine in familial Mediterranean fever—an inherited autoinflammatory disorder—in the late 20th century These studies then inspired testing of colchicine for pericarditis, which demonstrated that this agent reduced the risk of recurrent pericarditis by up to 50%. Colchicine remains a mainstay treatment for acute gout attacks, although the traditional strategy of administration until limited by gastrointestinal tolerance has given way to a regimen of 1.8 mg loading dose and 0.6 mg QD or BID.

- **TREATMENT OF CARDIOVASCULAR DISEASE WITH COLCHICINE**
- **Coronary Artery Disease**

The NLRP3 inflammasome activates the inflammatory cytokines interleukin-1 and interleukin-18 in response to molecular danger signals.[16] Both interleukin-1 and interleukin-

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 10| Issue: 11| November 2024|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2024: 8.402|| ISI Value

18 contribute to the genesis and progression of coronary atherosclerosis.[17] CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) validated the role of inflammation and interleukin-1 in atherosclerosis by demonstrating that blocking interleukin-1β with a monoclonal antibody reduced major adverse cardiovascular events without altering blood lipid levels.

Colchicine lowers hsCRP (high-sensitivity C-reactive protein) and may decrease coronary artery plaque volume. In an open-label, randomized clinical trial of colchicine versus no colchicine (LoDoCo [Low-Dose Colchicine]), colchicine lowered the risk of the composite of acute coronary syndrome (ACS), out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke by 67% in people with stable coronary artery disease.

More definitive evidence of the benefits of colchicine on atherosclerotic cardiovascular disease events comes from the LoDoCo2 trial and COLCOT (Colchicine Cardiovascular Outcomes Trial; LoDoCo2 and COLCOT each compared the effects of adding either low-dose colchicine (0.5 mg QD) or placebo to background guideline-directed medical therapy, including antiplatelet and statin therapy, on major adverse cardiovascular events in ≈5000 participants per trial over 2 years of follow-up. COLCOT enrolled individuals within 30 days of a myocardial infarction while LoDoCo2 enrolled individuals with chronic coronary artery disease (at least 6 months following an ACS). In both studies, low-dose colchicine lowered the risk of major adverse cardiovascular events by >30% compared with placebo. {3}

- **MECHANISMS OF ANTI-INFLAMMATORY EFFECTS OF COLCHICINE**

Colchicine binds tubulin, which interferes with microtubule-dependent cellular processes in rapidly dividing cells. Colchicine decreases interleukin-1β secretion by blocking the colocalization of the NLRP3 inflammasome components ASC and NLRP3 (but not the NLRC4 or AIM2 inflammasomes). These experiments suggest that colchicine can inhibit the systemic inflammatory response related to molecular patterns that can trigger NLRP3 while leaving other host defense mechanisms intact.

In people with non–ST-segment–elevation ACS, colchicine pretreatment before cardiac catheterization significantly lowered the transcoronary serum concentrations of interleukin-1β, interleukin-18, and interleukin-6 compared with no colchicine Similarly, colchicine lowered the levels of interleukin-1β secretion from ex vivo stimulated monocytes derived from people with an ACS. In a substudy of participants in the LoDoCo2 trial, colchicine significantly lowered NLRP3 protein levels in extracellular vesicles.[5]

3.Nitroglycerin

- **Benefits of nitroglycerin (glyceryl trinitrate or GTN)**

Despite advances in pharmacological therapies, ischemic heart disease and acute myocardial infarction (MI) continue to be a major cause of morbidity and death worldwide. According to the World Health Organization, over 7 million people die of ischemic heart disease every year. Consequently, novel pharmacological and non-pharmacological strategies need to be explored to benefit MI patients.

Since its discovery over 150 years ago, GTN has become the most common treatment for patients with unstable angina pectoris, myocardial infarction and heart failure. The ability of GTN to promote vasodilation as well as tolerance was clearly noted during the GTN industry ascension in the 20th century. Factory workers, usually exposed to high levels of organic nitrites, often complained of headaches on Mondays that disappeared over the weekends. Indeed, factory workers suffering from angina pectoris or heart failure often experienced relief from chest pain during the work week, but which recurred on weekends. Both effects were attributed to the vasodilator action of GTN, which quickly became apparent to physicians.

- **History of the therapeutic use of nitroglycerin**

In 1847, working in Theophile-Jules Pelouze's laboratory in Turin, Ascanio Sobrero discovered GTN. Sobrero first noted the aggressive headache for several hours produced by GTN. Two years later, knowing of Sobrero's reports of headache, the German scientist Constantin Hering tested GTN in healthy volunteers and observed that headache was caused with much precision.[4] Alfred Nobel joined Pelouze in 1851 and recognized the scientific and financial potential of GTN. Years later, he began manufacturing GTN in Sweden. Nobel suffered from poor health for most of his life. In later life, he suffered from intense pain and angina pectoris. It is therefore ironic that in 1890, his physicians recommended GTN for his heart compliant.

During the second half of the 19th century, several British scientists became interested in the newly discovered amyl nitrite, recognized as a powerful vasodilator. Lauder Brunton used the compound to relieve angina in 1867, and first reported the pharmacological resistance to repeated doses.[16, 17] Following Brunton's work, scientists concentrated on recording the effects of nitrite-containing compounds on several pathological systems, which include angina pectoris, myocardial infarction, hypertension and heart failure. Finally, GTN was established as a treatment for the relief of angina at the end of the 19th century. However, the mechanism of action of GTN-induced benefit was discovered only 80 years later. {12}

In the late 1970s, the vasodilator effect of GTN was discovered to be mediated by nitric oxide, which was apparently generated from GTN in vascular smooth muscle.Years later, it was discovered that mammalian cells synthesize nitric oxide. In 1998, approximately 130 years after the invention of dynamite by Alfred Nobel and the first observed clinical benefit of GTN, the Nobel Prize in Medicine or Physiology was awarded for "Nitric Oxide as a Signaling Molecule in the Cardiovascular System" to Robert Furchgott, Louis Ignarro and Ferid Murad. GTN remains the treatment of choice for relieving angina; other organic esters and inorganic nitrates are also used, but the rapid

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 10| Issue: 11| November 2024|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2024: 8.402|| ISI Value

action of GTN and its established efficacy make it the mainstay of angina pectoris relief.

- **Effects of GTN on Cardiac Cells**

The effects of GTN in the vasculature have been widely investigated, but relatively little is known about GTN's effect on cardiac cells. We have recently demonstrated that sustained treatment with GTN resulted in an increase in infarct size and cardiac dysfunction after myocardial infarction in rats.[52, 55] GTN tolerance-mediated deleterious effects in the heart are associated with ALDH2 inactivation As previously reported, GTN treatment drastically inhibits the dehydrogenase activity of recombinant ALDH2, *in vitro* and *in vivo*.[52] We also found that co-incubation with GTN and Alda-1 (a selective ALDH2 activator that we have identified) completely prevented GTN-induced recombinant ALDH2 inactivation. Further, sustained treatment with GTN significantly reduced mitochondrial ALDH2 activity in the rat myocardium, resulting in increased cardiac damage and ventricular dysfunction after a myocardial infarction event.[52] Of interest, co-treatment with GTN and Alda-1 restored ALDH2 activity, resulting in smaller infarct size and improved cardiac function in rats. We suggest that GTN tolerance is the main process involved in increased cardiac damage following MI, since the use of isosorbide dinitrate, an alternative NO donor often used in a sustained fashion to treat angina, did not cause ALDH2 inactivation and further cardiac damage *in vivo*.[52] Similarly, Sydow et al. observed that *in vivo* treatment with GTN leads to reduced cardiac GTN biotransformation by mitochondrial ALDH2 and resulted in accumulation of reactive oxygen species, where incubation of mitochondria from tolerant animals with reducing agents restored ALDH2 function. These findings suggest that patients under continuous GTN treatment are at risk for increased cardiac damage.

- **Cellular side effects of GTN**

The deleterious effects of organic nitrate therapy on mitochondrial were first described 55 years ago, where acute GTN exposure was described to induce mitochondrial swelling, to stimulated oxygen consumption and to caused loss of respiratory control of rat liver and heart mitochondria.[58] More recently, it was demonstrated that GTN infusion resulted in mitochondrial dysfunction-induced oxidative stress in both animal and human blood vessels.[59–61] An excessive reactive oxygen species production along with reduction of more than 50% in ALDH2 activity was observed in isolated mitochondria using the complex III inhibitor antimycin A.[62, 63] Mitochondrial-target antioxidants prevent complex I inhibition mediated by GTN treatment.[54] Therefore, accumulation of reactive aldehydes derived from oxidative stress may disrupt GTN bioactivation by negatively targeting ALDH2 function. Altogether, these findings suggest that GTN bioactivation requires functionally active mitochondria, since increased reactive oxygen species production due to mitochondrial dysfunction results in impaired ALDH2 activity and further GTN conversion.

We have recently found that sustained GTN treatment significantly decreases aldehyde dehydrogenase activity in the failing heart.[52] The fact that mammalian ALDH2 functions as a GTN reductase may explain the inhibitory effect of GTN on the aldehyde dehydrogenase activity. These findings point to a possible alcohol-GTN drug interaction through ALDH2 inactivation, which can result in a devastating phenomena induced by accumulation of reactive aldehydes inside the cell. However, this hypothesis needs to be better explored.[10]

- **Types of Heart Tests**

1. Blood Tests

Blood tests can tell a lot about your heart. They check stuff like cholesterol levels, triglycerides, and blood sugar, which can be signs of heart disease. Some common ones include:

Cardiac Troponin Test: This one helps diagnose heart attacks by detecting a protein called troponin that the heart releases into the bloodstream when it's damaged.

Lipid Profile: Measures cholesterol levels, specifically "bad" cholesterol (low-density lipoproteins), which can lead to heart disease.

Thyroid Function Tests: Checks your thyroid gland's activity. Thyroid issues can affect your heartbeat.

Complete Blood Count: Looks at different types of blood cells in your system. Abnormal counts can mimic heart issues.

B-type Natriuretic Peptide (BNP): Measures a protein called BNP, which increases when the heart has to work harder, often indicating heart failure.

2. Electrocardiogram (ECG or EKG)

This test checks your heart's electrical activity using pads on your chest. It's painless and tells the doc if your heart is beating as it should. It's handy for spotting irregular heartbeats, blocked arteries, damage, heart failure, or heart attacks.

3. Exercise Stress Test

Ever wonder how well your heart handles exercise? This test helps your doc find out. As you work out, your heart pumps more blood, and if there's an issue with the blood supply in your coronary arteries, this test will reveal it. It also guides your healthcare team on what kind of exercise is right for you.

4. Echocardiogram (Ultrasound)

Imagine it as a sonogram for your heart. It uses sound waves to create images of your heart's structure and function. Docs check your heart's walls, movement, pumping strength, valves, and even potential issues like regurgitation or stenosis.

5. Transesophageal Echocardiography (TEE)

TEE is like an upgraded echocardiogram. It uses ultrasound but via a tube that goes down your throat. This way, it gets super clear images of your heart's upper chambers and valves.

6. Nuclear Cardiac Stress Test (Myocardial Perfusion Imaging - MPI)

This test uses a smidge of radioactive stuff to show how blood flows through your heart. It's great for checking artery narrowing, damage from heart attacks, the effectiveness of stents or bypass surgery, and even if you need a coronary angiogram. You can be at rest during this test.

7. Coronary Angiogram (Cardiac Catheterization)

This one's like an X-ray for your heart. It uses a special dye to show how blood flows in your coronary arteries – those are the vessels that supply blood to your heart. It helps spot artery narrowing and diagnose coronary artery disease (CAD).

8. Magnetic Resonance Imaging (MRI)

A cardiac MRI uses magnets and radio waves to create detailed pictures of your heart and arteries. This test is for more complex

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 10| Issue: 11| November 2024|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2024: 8.402|| ISI Value

heart conditions and gives a closer look at blood vessels and heart function.

9. Coronary Computed Tomography Angiogram (CCTA)

Think of this as a 3D heart image created from X-rays. It's useful when other tests don't give enough info about your heart's health. CCTA shows heart structure, blood flow, plaque build up, and your risk for a heart attack.

10. Coronary Artery Calcium (CAC) Test

This test, also known as a heart scan, uses CT scans to spot calcium deposits in your coronary arteries. The more calcium, the higher your risk of heart disease. It helps with decisions like starting medication or therapy.

11. Holter Monitor

This nifty device is like a portable ECG machine. It records your heart's activity for 24 to 48 hours or even longer. It's used when heart symptoms come and go, giving doctors a good look at irregular heartbeats or arrhythmias.

12. Chest X-ray

A chest X-ray provides a snapshot of your heart, lungs, and chest bones. While it doesn't show the heart's inside structures, it helps locate, size, and shape the heart and lungs.

13. Nuclear Imaging Tests

These tests use radioactive tracers to create images of the heart. There are three types:

PET Scan: It helps diagnose coronary artery disease (CAD) and heart damage after an attack.

MUGA Scan: Measures ejection fraction, which shows how well your heart pumps blood.

SPECT Scan: Shows blood flow and heart function at rest and during exercise, helpful for detecting CAD or heart attack signs.

14. Tilt-Table Test

For those who often feel faint or lightheaded, this test measures how your blood pressure and heart rate react to changes in body position. It helps identify the cause of those sensations.

CONCLUSION

The management of heart attacks involves a multi-faceted approach, combining medication, lifestyle modifications, and in some cases, invasive procedures.

Medication plays a crucial role in both preventing and treating heart attacks. Various drug classes, including statins, aspirin, blood pressure medications, antiplatelet drugs, nitroglycerin, beta-blockers, thrombolytic drugs, and ACE inhibitors, have been shown to effectively reduce the risk of heart attacks and manage their acute and long-term effects.

However, it's important to emphasize that medication alone is not sufficient. Lifestyle changes such as quitting smoking, adopting a healthy diet, engaging in regular physical activity, and managing stress are essential components of heart health.

Regular medical checkups are also vital for early detection and management of risk factors. By working closely with healthcare providers, individuals can implement a comprehensive approach to heart health, significantly reducing their risk of heart attacks and improving their overall quality of life.

REFERENCE

1. *https://www.mayoclinic.org/diseases-conditions/heart-attack/symptoms-causes/syc-203731*
2. *https://www.medicalnewstoday.com/articles/321699*
3. *Heart Attack Treatment https://www.heart.org/en/health-topics/heart-attack/treatment-of-a-heart-attack*
4. *Aspirin Therapy in Heart Disease https://my.clevelandclinic.org/health/drugs/16761-aspirin-therapy-in-heart-disease*
5. *Colchicine's Role in Cardiovascular Disease Management https://www.ahajournals.org/doi/10.1161/ATVBAHA.124.319851*
6. *Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchic https://onlinelibrary.wiley.com/doi/abs/10.1002/art.27327*
7. *Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med. 1974;291:934–937. doi:10.1056/NEJM197410312911804 https://www.nejm.org/doi/abs/10.1056/NEJM197410312911804*
8. *Chiabrando JG, Bonaventura A, Vecchié A, Wohlford GF, Mauro AG, Jordan JH, Grizzard JD, Montecucco F, Berrocal DH, Brucato A, et al. Management of acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:76–92. doi:10.1016/j.jacc.2019.11.021 https://www.jacc.org/doi/abs/10.1016/j.jacc.2019.11.021*
9. *Nitroglycerin Use in Myocardial Infarction Patients: Risks and Benefits https://pmc.ncbi.nlm.nih.gov/articles/PMC3527093/*
10. *Palaniyandi SS, Ferreira JC, Brum PC, Mochly-Rosen D. PKCbetaII inhibition attenuates myocardial infarction induced heart failure and is associated with a reduction of fibrosis and pro-inflammatory responses. J Cell Mol Med. 2010;15:1769–1777. doi:10.1111/j.1582-4934.2010.01174.x. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1582-4934.2010.01174.x*
11. *Pereira MG, Ferreira JC, Bueno CR, Jr, Mattos KC, Rosa KT, Irigoyen MC, et al. Exercise training reduces cardiac angiotensin II levels and prevents cardiac dysfunction in a genetic model of sympathetic hyperactivity-induced heart failure in mice. Eur J Appl Physiol. 2009;105:843–850. doi:10.1007/s00421-008-0967-4 https://link.springer.com/article/10.1007/s00421-008-0967-4*
12. *Ignarro LJ. After 130 years, the molecular mechanism of action of nitroglycerin is revealed. Proc Natl Acad Sci U S A. 2002;99:7816–7817. doi:10.1073/pnas.132271799. https://www.pnas.org/doi/abs/10.1073/pnas.132271799*
Types of Heart tests https://health-e.in/blog/types-of-heart-tests/